Nanogen, Epoch Biosciences, IntegraGen, La Ligue Nationale Contre le Cancer, PerkinElmer, Procognia, Accelr8, Ciphergen | GenomeWeb

Nanogen Closes Acquisition of Epoch Biosciences

Nanogen last week closed its acquisition of Epoch Biosciences for $97 million. The deal was originally announced in September, and was approved by shareholders on Dec. 15.

Epoch ceased trading on the Nasdaq exchange at market close last Thursday.

Nanogen shareholders approved the issuance of shares of common stock for the deal, and also approved an amendment to the company’s certificate of incorporation increasing the number of authorized shares of Nanogen common stock to 135 million.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PNAS this week: variation patterns in wheat lines, regulatory variation in Capsella grandiflora, and more.

A Rockefeller University researcher is using edited ants to explore complex biological systems, the New York Times writes.

There's a heritable aspect to how much time people spend online, the Los Angeles Times reports.

Stat News reports that Joseph Gulfo is another contender for FDA commissioner.